PGRMC1在乳腺癌组织中的表达及其与临床病理特征的相关性

doi:10.3969/j.issn.1006-7795.2018.02.021

摘要/Abstract

摘要： 目的分析免疫组织化学指标孕激素受体膜组分1（progesterone receptor membrane component 1，PGRMC1）、雌激素受体（estrogen receptor，ER）、孕激素受体（progestogen receptor，PR）、Ki-67和Her-2（human epidermal growth factor receptor-2，Her-2）在乳腺癌组织、乳腺良性肿瘤组织和正常乳腺组织中的表达情况，并分别评估PGRMC1在乳腺癌和乳腺良性肿瘤组织中的表达与其他各指标的相关性。方法选取2015年9月至2017年1月间乳腺癌组织标本60例、乳腺良性肿瘤组织标本30例和正常乳腺组织标本30例（来自经乳腺麦默通微创旋切良性肿瘤周围1cm左右的正常组织，病理证实乳腺组织无异常者）。所有组织来源者在术前经空心针活检或经术后病理组织学检查确诊。采用免疫组织化学方法分别检测乳腺癌组织、乳腺良性肿瘤组织和正常乳腺组织中的PGRMC1、ER、PR、Ki-67和Her-2的表达情况，并分析PGRMC1在乳腺癌和乳腺良性肿瘤组织中的表达与其他各指标的相关性。结果 PGRMC1表达率：乳腺癌组（68.3%） > 乳腺良性肿瘤组（26.7%） > 正常对照组（6.7%），组间差异有统计学意义（P<0.01）。ER表达率：乳腺癌组（58.3%） > 乳腺良性肿瘤组（43.3%） > 正常对照组（23.3%），组间差异有统计学意义（P<0.01）。Ki-67表达率：乳腺癌组（66.7%） > 乳腺良性肿瘤组（36.7%） > 正常对照组（13.3%），组间差异有统计学意义（P<0.01）。乳腺癌组PGRMC1的表达与ER表达呈正相关（OR=3.593，95%CI：1.131~11.418），与PR、Ki-67和Her-2的表达无相关性。结论乳腺癌组PGRMC1的表达水平显著高于乳腺良性肿瘤组和正常对照组；乳腺癌组织中PGRMC1的表达与ER表达呈正相关，与PR、Ki-67和Her-2表达无相关性。

关键词: 乳腺癌, 免疫组织化学, 孕激素受体膜组分1, 雌激素受体, 孕激素受体, Ki-67, Her-2, 相关性

Abstract: Objective To analyse the expression profile of immunohistochemical indicators progesterone receptor membrane component 1 (PGRMC1), estrogen receptor (ER), progestogen receptor (PR), Ki-67 and human epidermal growth factor receptor-2 (Her-2) in breast cancer tissues, benign breast tumor tissues and normal breast tissues, and evaluate the correlations between the expressions of PGRMC1 and other indicators in breast cancer tissues and benign breast tumor tissues. Methods Sixty cases of breast cancer tissue samples, 30 cases of benign breast tumor tissue and 30 cases of normal breast tissue samples (from the breast benign tumor mammotome minimally invasive rotary cutting around 1 cm of normal tissue, pathological assay revealed no abnormal breast tissue) were selected between September 2015 and January 2015. All the sources of the tissues were diagnosed by a hollow needle biopsy or postoperative histologic examination. Immunohistochemical method was used to detect breast cancer tissues, benign breast tumor tissues and normal breast tissues in the expression of PGRMC1, ER, PR, Ki-67 and Her-2, and analyze the correlations of PGRMC1 expression in breast cancer and benign breast tumor tissues with other indicators. Results Expression rate of PGRMC1:breast cancer group (68.3%) > benign breast tumor group (26.7%) > normal control group (6.7%), the difference between groups was statistically significant (P<0.01). Expression rate of ER:breast cancer group (58.3%) > benign breast tumor group (43.3%) > normal control group (23.3%), the difference between groups was statistically significant (P<0.01). Expression rate of ki-67:breast cancer group (66.7%) > benign breast tumor group (36.7%) > normal control group (13.3%), the difference between groups was statistically significant (P<0.01). The expression of PGRMC1 in breast cancer group was positively correlated with ER expression (OR=3.593,95%CI:1.131-11.418), and there was no correlation with the expressions of PR, ki-67 and Her-2. Conclusion The expression level of PGRMC1 in breast cancer group was significantly higher than that in benign breast tumor group and control. The expression of PGRMC1 in breast cancer tissue was positively correlated with ER expression, and there was no correlation with PR, ki-67 and Her-2 expression.

Key words: breast cancer, immunohistochemistry, progesterone receptor membrane component 1(PGRMC1), estrogen receptor, progestogen receptor, Ki-67, human epidermal growth factor receptor-2, correlation

中图分类号:

G306.4

王利娟, 阮祥燕, 赵越. PGRMC1在乳腺癌组织中的表达及其与临床病理特征的相关性[J]. 首都医科大学学报, 2018, 39(2): 272-276.

Wang Lijuan, Ruan Xiangyan, Zhao Yue. Expression of PGRMC1 in breast cancer tissue and its correlation with clinicopathological features[J]. Journal of Capital Medical University, 2018, 39(2): 272-276.

参考文献

[1] Fan L, Strasser-Weippl K, Li J J, et, al. Breast cancer in China[J]. Lancet Oncol,2014,15(7):e279-289.
[2] Beral V. Million women study collaborators. Breast cancer and hormone-replacement therapy in the million women study[J]. Lancet, 2003, 362(9382):419-427.
[3] Chlebowski R T, Hendrix S L, Langer R D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women:the Women's Health initiative randomized trial[J]. JAMA, 2003,289:3243-3253.
[4] Fournier A, Berrino F, Clavel-Chapelon F.Unequal risks for breast cancer associated with different hormone replacement therapies:results from the E3N cohort study[J]. Breast Cancer Res Treat, 2008, 107(1):103-111.
[5] Jeng M H, Parker C J, Jordan V C. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation[J]. Cancer Res, 1992,52(23):6539-6546.
[6] Neubauer H, Ruan X, Schneck H. Overexpression of progesterone receptor membrane component 1:possible mechanism for increased breast cancer risk with norethisterone in hormone therapy[J]. Menopause, 2013,20(5):504-510.
[7] Ruan X, Neubauer H, Yang Y, Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells[J]. Climacteric, 2012,15(5):467-472.
[8] Cahill M A. Progesterone receptor membrane component 1:an integrative review[J]. J Steroid Biochem Mol Biol, 2007, 105(1-5):16-36.
[9] Selmin O, Lucier G W, Clark G C, et al. Isolation and characterization of a novel gene induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver[J]. Carcinogenesis,1996, 17(12):2609-2615.
[10] Crudden G, Loesel R, Craven R J. Overexpression of the cytochrome p450 activator hpr6(heme-1 domain protein/human progesterone receptor) in tumors[J]. Tumour Biol,2005, 26(3):142-146.
[11] Mir S U, Ahmed I S, Arnold S, et al. Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients[J]. Int J Cancer, 2012, 131(2):E1-9.
[12] Clark N C, Friel A M, Pru C A, et,al. Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors[J]. Cancer Biol Ther, 2016,17(3):262-271.
[13] Hammond M E, Hayes D F, Wolff A C, et al. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Oncol Pract, 2010,6(4):195-197.
[14] Wolff A C, Hammond M E, Hicks D G, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. J Clin Oncol,2013,31(31):3997-4013.
[15] 张颖,阮祥燕,米鑫,等.孕激素受体膜组分1(PGRMC1)对预测乳腺癌预后作用的研究[J].首都医科大学学报,2015,36(4):548-552.
[16] Crudden G, Loesel R, Craven R J.Overexpression of the cytochrome p450 activator hpr6(heme-1 domain protein/human progesterone receptor) in tumors[J]. Tumour Biol,2005,26(3):142-146.
[17] Ji S F, Wu A G, Yang H F. Expression of progesterone receptor membrane component-1 is associated with the malignant phenotypes of breast cancer[J].Nan Fang Yi Ke Da Xue Xue Bao, 2012,32(5):635-638.
[18] Causey M W, Huston L J, Harold D M,et al. Transcriptional analysis of novel hormone receptors PGRMC1 and PGRMC2 as potential biomarkers of breast adenocarcinoma staging[J]. J Surg Res,2011,171(2):615-622.
[19] Marina W, Isabel W, Christoph M, et al. High Level of progesteron receptor membrane component 1(PGRMC 1) in tissue of breast cancer patients is associated with worse response to anthracycline-based neoadjuvant therapy[J]. Horm Metab Res,2017,49(8):595-603.
[20] 纪术峰. PGRMC1调节乳腺癌细胞化疗敏感性的研究[D].广州:南方医科大学,2012.
[21] Neubauer H, Clare S E, Wozny W, et, al. Breast cancer proteomics reveals correlation between estrogen receptor status and differentialphosphorylation of PGRMC1[J]. Breast Cancer Res,2008,10(5):R85.
[22] 杨华锋,纪术峰,李占文,等.PGRMC1在三阴性乳腺癌中的表达及其与ki-67的相关性[J].中国现代医生,2016,54(34):8-12,169.